In accordance, Ahn et al. reported that mutations in KRAS codon 13 generally exhibit lower aggressiveness and are less likely to function as adverse prognostic markers for CRC than mutations in codon 12 [37]. This evidence concerns the gene KRAS and colorectal carcinoma.